I bought 600 shares at $18 looking for $27 on a technical breakout by a company in a hot group. Very small float also.
Sentiment: Strong Buy
SNY will divest MNKD from its diabetes portfolio by year end,
With Lantus going off patent Toujeo will crush. Why woud Sanofi even bother with a niche product like Affreza. Heck, anyone with any respiratory history can't use it, spirometry or not.
True, but I believe you are underestimating the amount of diabetics, like myself, with asthma that cannot use Affrezza. I will move to to Toujeo. GLTA